ArticlePharmacoEconomics2018

Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.

Verin Lertjanyakun et al.PubMed ↗Publisher ↗

No numbers read from the abstract.